Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Harry Ehrlich who wrote (1116)	2/15/1998 3:59:00 PM
From: D.Right	Respond to of 2173

Dear Harry: Thanks for the detailed list of insider activity, looks pretty convincing that the insiders like their chance. I thought AMLN was going to report their quarter last week then realized this is the quarter they report their year and last year was reported on the 27th of Feb. I guess two more weeks to go. As for the 75% number, I won't be surprised if they mention it in their annual report, if they have told the H&Q Conf. then they should tell it to all the shareholders. As you have given your reasons for coming back to the stock, I will give mine again for loving it all the way. 1. A pretty much lock on type I approval. 2. Good percentage adoption by both type I and II patients. 3. One product is bad if it fails, however, one product is good if it is big and successful, which means not wasting money on others that may not be successful. 4. True, it is still a long way to NDA in about two years, but enrollment completion in first and second quarters and trial results by year end in 1998 will bring attention back to AMLN in a big way. Time will tell. Good luck to you. D.Right